Lifecore Biomedical Inc (NAS:LFCR)

Q4 2025 Lifecore Biomedical Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $7.76 (+0.39%)

Transcript 10-K8-K

Key Points

Positve

Lifecore Biomedical Inc (LFCR) successfully signed multiple new development agreements, including 9 new programs with new customers, which will drive near-term momentum.
The company achieved its stated financial guidance for both revenue and adjusted EBITDA for fiscal 2025.
Lifecore Biomedical Inc (LFCR) made significant progress in executing its growth strategies, including maximizing existing customer business and advancing late-stage development programs.
The company improved operational efficiency by right-sizing its workforce and enhancing productivity, resulting in a 97% on-time delivery rate.
Lifecore Biomedical Inc (LFCR) strengthened its balance sheet by raising capital and selling non-core assets, aligning capital assets with operational needs.

Negative

Revenues for the fourth quarter decreased by 4% compared to the prior year, primarily due to a $5.6 million decrease in CDMO revenues.
Gross profit for the fourth quarter declined by $3.3 million, mainly due to a decrease in CDMO gross profit impacted by sales mix and lower development revenue.
The company recorded a net loss of $1.1 million for the fourth quarter, although this was an improvement from the previous year's loss.
Selling, general, and administrative expenses increased for the fiscal year, primarily due to a rise in non-cash stock-based compensation.
The company faces potential headwinds from tariffs on imported pharmaceuticals, which could impact future business development and customer conversations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LFCR.OQ - Lifecore Biomedical Inc
Q4 2025 Lifecore Biomedical Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and thank you for joining Life course fiscal 2025 4th quarter and full year earnings call. During the call, all participants will be in a listen-only mode. Now, I would like to turn the call over to Stephanie Diaz, manager of investor relations for LifeCorp.

Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and thank you for joining us today to discuss LiveCorp Biomedical's 4th quarter and full year fiscal 2025 earnings results. Hosting the call today from LiveCorp are Paul Josephs, President and Chief Executive Officer,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.